A Boundary-Aware Synthesis of Wearable Hydrogel Biosensing And Clinical Risk Prediction: Robust Evaluation under Distribution Shift

Abstract

Two distinct lines of inquiry—dynamic-covalent hydrogel sensing combined with machine learning for Parkinsonian assessment and encrypted interaction and a clinical nomogram and web calculator for individualized lymph-node-metastasis risk—converge on a practical question for wearable hydrogel biosensing and clinical risk prediction: what evidence is needed before a reported advantage becomes a defensible basis for explanation, comparison, or deployment? Two target papers are triangulated against 12 locally validated publications. The comparison follows network chemistry, mechanical compliance, signal stability, clinical features, privacy and deliberately separates mechanistic interpretation from performance ranking, because the latter can conceal incompatible experimental or operational conditions. The combined literature indicates that methodological gains become actionable only when network chemistry and mechanical compliance are evaluated together and when limits associated with privacy are explicit. This shifts the emphasis from isolated scores toward traceable chains of evidence and decision relevance. The resulting framework supports reproducible comparison while preserving differences between study designs, and it identifies concrete points at which transfer claims should be narrowed or retested.